Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 144

1.

Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial.

Martin-Broto J, Stacchiotti S, Lopez-Pousa A, Redondo A, Bernabeu D, de Alava E, Casali PG, Italiano A, Gutierrez A, Moura DS, Peña-Chilet M, Diaz-Martin J, Biscuola M, Taron M, Collini P, Ranchere-Vince D, Garcia Del Muro X, Grignani G, Dumont S, Martinez-Trufero J, Palmerini E, Hindi N, Sebio A, Dopazo J, Dei Tos AP, LeCesne A, Blay JY, Cruz J.

Lancet Oncol. 2019 Jan;20(1):134-144. doi: 10.1016/S1470-2045(18)30676-4. Epub 2018 Dec 18.

PMID:
30578023
2.

[Molecular biology of castration resistant prostate cancer.]

Medina-López RA, Tarón M, Osman-García I, Duran I.

Arch Esp Urol. 2018 Sep;71(8):639-650. Review. Spanish.

PMID:
30319124
3.

Nilotinib as Coadjuvant Treatment with Doxorubicin in Patients with Sarcomas: A Phase I Trial of the Spanish Group for Research on Sarcoma.

Alemany R, Moura DS, Redondo A, Martinez-Trufero J, Calabuig S, Saus C, Obrador-Hevia A, Ramos R, Villar VH, Valverde C, Vaz MA, Medina J, Felipe-Abrio I, Hindi N, Taron M, Martin-Broto J.

Clin Cancer Res. 2018 Nov 1;24(21):5239-5249. doi: 10.1158/1078-0432.CCR-18-0851. Epub 2018 Jul 23.

PMID:
30037815
4.

Gene expression analyses determine two different subpopulations in KIT-negative GIST-like (KNGL) patients.

Moura DS, Ramos R, Fernandez-Serra A, Serrano T, Cruz J, Alvarez-Alegret R, Ortiz-Duran R, Vicioso L, Gomez-Dorronsoro ML, Garcia Del Muro X, Martinez-Trufero J, Rubio-Casadevall J, Sevilla I, Lainez N, Gutierrez A, Serrano C, Lopez-Alvarez M, Hindi N, Taron M, López-Guerrero JA, Martin-Broto J.

Oncotarget. 2018 Apr 3;9(25):17576-17588. doi: 10.18632/oncotarget.24799. eCollection 2018 Apr 3.

5.

Single nucleotide polymorphisms as prognostic and predictive biomarkers in renal cell carcinoma.

Garrigós C, Espinosa M, Salinas A, Osman I, Medina R, Taron M, Molina-Pinelo S, Duran I.

Oncotarget. 2017 Nov 20;8(63):106551-106564. doi: 10.18632/oncotarget.22533. eCollection 2017 Dec 5.

6.

Gemcitabine plus sirolimus for relapsed and progressing osteosarcoma patients after standard chemotherapy: a multicenter, single-arm phase II trial of Spanish Group for Research on Sarcoma (GEIS).

Martin-Broto J, Redondo A, Valverde C, Vaz MA, Mora J, Garcia Del Muro X, Gutierrez A, Tous C, Carnero A, Marcilla D, Carranza A, Sancho P, Martinez-Trufero J, Diaz-Beveridge R, Cruz J, Encinas V, Taron M, Moura DS, Luna P, Hindi N, Lopez-Pousa A.

Ann Oncol. 2017 Dec 1;28(12):2994-2999. doi: 10.1093/annonc/mdx536.

PMID:
29045512
7.

Combinatory effect of BRCA1 and HERC2 expression on outcome in advanced non-small-cell lung cancer.

Bonanno L, Costa C, Majem M, Sanchez JJ, Rodriguez I, Gimenez-Capitan A, Molina-Vila MA, Vergnenegre A, Massuti B, Favaretto A, Rugge M, Pallares C, Taron M, Rosell R.

BMC Cancer. 2016 May 14;16:312. doi: 10.1186/s12885-016-2339-5.

8.

Aberrant gene methylation and bronchial dysplasia in high risk lung cancer patients.

Rosell A, Rodríguez N, Monsó E, Taron M, Millares L, Ramírez JL, López-Lisbona R, Cubero N, Andreo F, Sanz J, Llatjós M, Llatjós R, Fernández-Figueras MT, Mate JL, Català I, Setó L, Roset M, Díez-Ferrer M, Dorca J.

Lung Cancer. 2016 Apr;94:102-7. doi: 10.1016/j.lungcan.2016.02.003. Epub 2016 Feb 11.

PMID:
26973214
9.

Carcinosarcoma of the upper urinary tract with an aggressive angiosarcoma component.

Cuadra-Urteaga JL, Font A, Tapia G, Areal J, Taron M.

Cancer Biol Ther. 2016;17(3):233-6. doi: 10.1080/15384047.2016.1139237. Epub 2016 Feb 18.

10.

Pharmacogenetics and pharmacogenomics as tools in cancer therapy.

Rodríguez-Vicente AE, Lumbreras E, Hernández JM, Martín M, Calles A, Otín CL, Algarra SM, Páez D, Taron M.

Drug Metab Pers Ther. 2016 Mar;31(1):25-34. doi: 10.1515/dmpt-2015-0042. Review.

11.

Total Synthesis of Amphirionin-4.

Holmes M, Kwon D, Taron M, Britton R.

Org Lett. 2015 Aug 7;17(15):3868-71. doi: 10.1021/acs.orglett.5b01844. Epub 2015 Jul 14.

PMID:
26172382
12.

Pharmacogenomic biomarkers for personalized cancer treatment.

Rodríguez-Antona C, Taron M.

J Intern Med. 2015 Feb;277(2):201-217. doi: 10.1111/joim.12321. Review.

13.

Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors.

Rolfo C, Giovannetti E, Hong DS, Bivona T, Raez LE, Bronte G, Buffoni L, Reguart N, Santos ES, Germonpre P, Taron M, Passiglia F, Van Meerbeeck JP, Russo A, Peeters M, Gil-Bazo I, Pauwels P, Rosell R.

Cancer Treat Rev. 2014 Sep;40(8):990-1004. doi: 10.1016/j.ctrv.2014.05.009. Epub 2014 Jun 6. Review.

PMID:
24953979
14.

Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression.

Reguart N, Rosell R, Cardenal F, Cardona AF, Isla D, Palmero R, Moran T, Rolfo C, Pallarès MC, Insa A, Carcereny E, Majem M, De Castro J, Queralt C, Molina MA, Taron M.

Lung Cancer. 2014 May;84(2):161-7. doi: 10.1016/j.lungcan.2014.02.011. Epub 2014 Mar 2.

PMID:
24636848
15.

Clinical validation of a PCR assay for the detection of EGFR mutations in non-small-cell lung cancer: retrospective testing of specimens from the EURTAC trial.

Benlloch S, Botero ML, Beltran-Alamillo J, Mayo C, Gimenez-Capitán A, de Aguirre I, Queralt C, Ramirez JL, Ramón y Cajal S, Klughammer B, Schlegel M, Bordogna W, Chen D, Zhang G, Kovach B, Shieh F, Palma JF, Wu L, Lawrence HJ, Taron M.

PLoS One. 2014 Feb 25;9(2):e89518. doi: 10.1371/journal.pone.0089518. eCollection 2014.

16.

The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial.

Costa C, Molina MA, Drozdowskyj A, Giménez-Capitán A, Bertran-Alamillo J, Karachaliou N, Gervais R, Massuti B, Wei J, Moran T, Majem M, Felip E, Carcereny E, Garcia-Campelo R, Viteri S, Taron M, Ono M, Giannikopoulos P, Bivona T, Rosell R.

Clin Cancer Res. 2014 Apr 1;20(7):2001-10. doi: 10.1158/1078-0432.CCR-13-2233. Epub 2014 Feb 3.

17.

Molecular profiles of non-small cell lung cancers in cigarette smoking and never-smoking patients.

Szymanowska-Narloch A, Jassem E, Skrzypski M, Muley T, Meister M, Dienemann H, Taron M, Rosell R, Rzepko R, Jarząb M, Marjański T, Pawłowski R, Rzyman W, Jassem J.

Adv Med Sci. 2013;58(2):196-206. doi: 10.2478/ams-2013-0025.

PMID:
24451080
18.

The predictive value of 53BP1 and BRCA1 mRNA expression in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy.

Bonanno L, Costa C, Majem M, Sanchez JJ, Gimenez-Capitan A, Rodriguez I, Vergnenegre A, Massuti B, Favaretto A, Rugge M, Pallares C, Taron M, Rosell R.

Oncotarget. 2013 Oct;4(10):1572-81.

19.

A prognostic DNA methylation signature for stage I non-small-cell lung cancer.

Sandoval J, Mendez-Gonzalez J, Nadal E, Chen G, Carmona FJ, Sayols S, Moran S, Heyn H, Vizoso M, Gomez A, Sanchez-Cespedes M, Assenov Y, Müller F, Bock C, Taron M, Mora J, Muscarella LA, Liloglou T, Davies M, Pollan M, Pajares MJ, Torre W, Montuenga LM, Brambilla E, Field JK, Roz L, Lo Iacono M, Scagliotti GV, Rosell R, Beer DG, Esteller M.

J Clin Oncol. 2013 Nov 10;31(32):4140-7. doi: 10.1200/JCO.2012.48.5516. Epub 2013 Sep 30.

20.

EGFR mutation analysis in sputum of lung cancer patients: a multitechnique study.

Hubers AJ, Heideman DA, Yatabe Y, Wood MD, Tull J, Tarón M, Molina MA, Mayo C, Bertran-Alamillo J, Herder GJ, Koning R, Sie D, Ylstra B, Meijer GA, Snijders PJ, Witte BI, Postmus PE, Smit EF, Thunnissen E.

Lung Cancer. 2013 Oct;82(1):38-43. doi: 10.1016/j.lungcan.2013.07.011. Epub 2013 Aug 5.

PMID:
23927883
21.

Cross-validation analysis of the prognostic significance of mucin expression in patients with resected non-small cell lung cancer treated with adjuvant chemotherapy: results from IALT, JBR.10 and ANITA.

Graziano SL, Lacas B, Vollmer R, Kratzke R, Popper H, Filipits M, Seymour L, Shepherd FA, Rosell R, Veillard AS, Taron M, Pignon JP.

Lung Cancer. 2013 Oct;82(1):149-55. doi: 10.1016/j.lungcan.2013.06.015. Epub 2013 Aug 4.

22.

Variants in phospholipid metabolism and upstream regulators and non-small cell lung cancer susceptibility.

Cebrián A, Taron M, Sala N, Ardanaz E, Chirlaque MD, Larrañaga N, Redondo ML, Sánchez MJ, Gómez del Pulgar T, Camps C, Rosell R, González CA, Lacal JC.

Clin Transl Oncol. 2014 Jan;16(1):107-12. doi: 10.1007/s12094-013-1080-7. Epub 2013 Jul 30.

PMID:
23896864
23.

Main histologic types of non-small-cell lung cancer differ in expression of prognosis-related genes.

Skrzypski M, Dziadziuszko R, Jassem E, Szymanowska-Narloch A, Gulida G, Rzepko R, Biernat W, Taron M, Jelitto-Górska M, Marjański T, Rzyman W, Rosell R, Jassem J.

Clin Lung Cancer. 2013 Nov;14(6):666-673.e2. doi: 10.1016/j.cllc.2013.04.010. Epub 2013 Jul 17.

PMID:
23870818
24.

Treatment and detection of ALK-rearranged NSCLC.

Peters S, Taron M, Bubendorf L, Blackhall F, Stahel R.

Lung Cancer. 2013 Aug;81(2):145-54. doi: 10.1016/j.lungcan.2013.03.017. Epub 2013 Jun 12. Review.

PMID:
23769207
25.

CK-coated magnetic-based beads as a tool to isolate circulating tumor cells (CTCs) in human tumors.

Mayo C, Ortega FG, Giménez-Capitán A, Molina-Vila MA, Serrano MJ, Viteri S, Costa C, Gascó A, Bertran-Alamillo J, Karachaliou N, Lorente JA, Tarón M, Rosell R.

Transl Lung Cancer Res. 2013 Apr;2(2):65-71. doi: 10.3978/j.issn.2218-6751.2013.02.06.

26.

Guideline on the requirements of external quality assessment programs in molecular pathology.

van Krieken JH, Normanno N, Blackhall F, Boone E, Botti G, Carneiro F, Celik I, Ciardiello F, Cree IA, Deans ZC, Edsjö A, Groenen PJ, Kamarainen O, Kreipe HH, Ligtenberg MJ, Marchetti A, Murray S, Opdam FJ, Patterson SD, Patton S, Pinto C, Rouleau E, Schuuring E, Sterck S, Taron M, Tejpar S, Timens W, Thunnissen E, van de Ven PM, Siebers AG, Dequeker E.

Virchows Arch. 2013 Jan;462(1):27-37. doi: 10.1007/s00428-012-1354-4. Epub 2012 Dec 19.

PMID:
23250354
27.

Prospective assessment of XRCC3, XPD and Aurora kinase A single-nucleotide polymorphisms in advanced lung cancer.

Provencio M, Camps C, Cobo M, De las Peñas R, Massuti B, Blanco R, Alberola V, Jimenez U, Delgado JR, Cardenal F, Tarón M, Ramírez JL, Sanchez A, Rosell R.

Cancer Chemother Pharmacol. 2012 Dec;70(6):883-90. doi: 10.1007/s00280-012-1985-9. Epub 2012 Sep 29.

PMID:
23053267
28.

Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer.

Pérol M, Chouaid C, Pérol D, Barlési F, Gervais R, Westeel V, Crequit J, Léna H, Vergnenègre A, Zalcman G, Monnet I, Le Caer H, Fournel P, Falchero L, Poudenx M, Vaylet F, Ségura-Ferlay C, Devouassoux-Shisheboran M, Taron M, Milleron B.

J Clin Oncol. 2012 Oct 1;30(28):3516-24. Epub 2012 Sep 4.

PMID:
22949150
29.

Mouse p53-deficient cancer models as platforms for obtaining genomic predictors of human cancer clinical outcomes.

Dueñas M, Santos M, Aranda JF, Bielza C, Martínez-Cruz AB, Lorz C, Taron M, Ciruelos EM, Rodríguez-Peralto JL, Martín M, Larrañaga P, Dahabreh J, Stathopoulos GP, Rosell R, Paramio JM, García-Escudero R.

PLoS One. 2012;7(8):e42494. doi: 10.1371/journal.pone.0042494. Epub 2012 Aug 7.

30.

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.

Zhang Z, Lee JC, Lin L, Olivas V, Au V, LaFramboise T, Abdel-Rahman M, Wang X, Levine AD, Rho JK, Choi YJ, Choi CM, Kim SW, Jang SJ, Park YS, Kim WS, Lee DH, Lee JS, Miller VA, Arcila M, Ladanyi M, Moonsamy P, Sawyers C, Boggon TJ, Ma PC, Costa C, Taron M, Rosell R, Halmos B, Bivona TG.

Nat Genet. 2012 Jul 1;44(8):852-60. doi: 10.1038/ng.2330.

31.

Biological markers of cisplatin resistance in advanced testicular germ cell tumours.

García-Velasco A, Durán I, García E, Tarón M, Ballestín C, Castellanos D, Cortés-Funés H, Paz-Ares L.

Clin Transl Oncol. 2012 Jun;14(6):452-7. doi: 10.1007/s12094-012-0823-1.

PMID:
22634534
32.

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L; Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica.

Lancet Oncol. 2012 Mar;13(3):239-46. doi: 10.1016/S1470-2045(11)70393-X. Epub 2012 Jan 26.

PMID:
22285168
33.

Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum.

Massuti B, Cobo M, Camps C, Dómine M, Provencio M, Alberola V, Viñolas N, Rosell R, Tarón M, Gutiérrez-Calderón V, Lardelli P, Alfaro V, Nieto A, Isla D.

Lung Cancer. 2012 Jun;76(3):354-61. doi: 10.1016/j.lungcan.2011.12.002. Epub 2011 Dec 23.

PMID:
22197612
34.

Role of genotyping in non-small cell lung cancer treatment: current status.

Bonanno L, Favaretto A, Rugge M, Taron M, Rosell R.

Drugs. 2011 Dec 3;71(17):2231-46. doi: 10.2165/11597700-000000000-00000. Review.

PMID:
22085382
35.

mRNA expression levels and genetic status of genes involved in the EGFR and NF-κB pathways in metastatic non-small-cell lung cancer patients.

Santarpia M, Magri I, Sanchez-Ronco M, Costa C, Molina-Vila MA, Gimenez-Capitan A, Bertran-Alamillo J, Mayo C, Benlloch S, Viteri S, Gasco A, Mederos N, Carcereny E, Taron M, Rosell R.

J Transl Med. 2011 Sep 27;9:163. doi: 10.1186/1479-5876-9-163.

36.

Tumour and serum MGMT promoter methylation and protein expression in glioblastoma patients.

Balańa C, Carrato C, Ramírez JL, Cardona AF, Berdiel M, Sánchez JJ, Tarón M, Hostalot C, Musulen E, Ariza A, Rosell R.

Clin Transl Oncol. 2011 Sep;13(9):677-85. doi: 10.1007/s12094-011-0714-x.

PMID:
21865140
37.

mRNA expression of BRCA1, PIAS1, and PIAS4 and survival after second-line docetaxel in advanced gastric cancer.

Wei J, Costa C, Ding Y, Zou Z, Yu L, Sanchez JJ, Qian X, Chen H, Gimenez-Capitan A, Meng F, Moran T, Benlloch S, Taron M, Rosell R, Liu B.

J Natl Cancer Inst. 2011 Oct 19;103(20):1552-6. doi: 10.1093/jnci/djr326. Epub 2011 Aug 23.

PMID:
21862729
38.

Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma.

Girard N, Sima CS, Jackman DM, Sequist LV, Chen H, Yang JC, Ji H, Waltman B, Rosell R, Taron M, Zakowski MF, Ladanyi M, Riely G, Pao W.

Eur Respir J. 2012 Feb;39(2):366-72. doi: 10.1183/09031936.00010111. Epub 2011 Jul 20.

39.

Chemotherapy-induced neutropenia does not correlate with DNA repair gene polymorphisms and treatment efficacy in advanced non-small-cell lung cancer patients.

Iranzo V, Sirera R, Bremnes RM, Blasco A, Jantus-Lewintre E, Tarón M, Berrocal A, Blasco S, Caballero C, Del Pozo N, Rosell R, Camps C.

Clin Lung Cancer. 2011 Jul;12(4):224-30. doi: 10.1016/j.cllc.2011.03.023. Epub 2011 Apr 24.

PMID:
21726821
40.

Fifth Educational Symposium of the Spanish Lung Cancer Group: report on the Molecular Biology Workshop.

Bover I, Rolfo C, Jantus-Lewintre E, Sirera R, Camps C, Chaib I, Ramirez-Serrano JL, Benlloch S, Molina-Vila MA, Simonetti S, Costa C, Gimenez-Capitan A, Mendez P, Taron M, Rosell R.

Lung Cancer. 2011 Dec;74(3):535-43. doi: 10.1016/j.lungcan.2011.04.016. Epub 2011 May 25.

PMID:
21616552
41.

A modified host-cell reactivation assay to quantify DNA repair capacity in cryopreserved peripheral lymphocytes.

Mendez P, Taron M, Moran T, Fernandez MA, Requena G, Rosell R.

DNA Repair (Amst). 2011 Jun 10;10(6):603-10. doi: 10.1016/j.dnarep.2011.04.001. Epub 2011 May 5.

PMID:
21546323
42.

Genome-wide association study of survival in non-small cell lung cancer patients receiving platinum-based chemotherapy.

Wu X, Ye Y, Rosell R, Amos CI, Stewart DJ, Hildebrandt MA, Roth JA, Minna JD, Gu J, Lin J, Buch SC, Nukui T, Ramirez Serrano JL, Taron M, Cassidy A, Lu C, Chang JY, Lippman SM, Hong WK, Spitz MR, Romkes M, Yang P.

J Natl Cancer Inst. 2011 May 18;103(10):817-25. doi: 10.1093/jnci/djr075. Epub 2011 Apr 11.

43.

Combined VEGF-A and VEGFR-2 concentrations in plasma: diagnostic and prognostic implications in patients with advanced NSCLC.

Jantus-Lewintre E, Sanmartín E, Sirera R, Blasco A, Sanchez JJ, Tarón M, Rosell R, Camps C.

Lung Cancer. 2011 Nov;74(2):326-31. doi: 10.1016/j.lungcan.2011.02.016. Epub 2011 Apr 9.

PMID:
21481963
44.

Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials.

Reiman T, Lai R, Veillard AS, Paris E, Soria JC, Rosell R, Taron M, Graziano S, Kratzke R, Seymour L, Shepherd FA, Pignon JP, Sève P; LACE-Bio Group.

Ann Oncol. 2012 Jan;23(1):86-93. doi: 10.1093/annonc/mdr033. Epub 2011 Apr 6.

45.

FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR.

Bivona TG, Hieronymus H, Parker J, Chang K, Taron M, Rosell R, Moonsamy P, Dahlman K, Miller VA, Costa C, Hannon G, Sawyers CL.

Nature. 2011 Mar 24;471(7339):523-6. doi: 10.1038/nature09870.

46.

Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: a retrospective multicentric study.

Schöffski P, Taron M, Jimeno J, Grosso F, Sanfilipio R, Casali PG, Le Cesne A, Jones RL, Blay JY, Poveda A, Maki RG, Nieto A, Tercero JC, Rosell R.

Eur J Cancer. 2011 May;47(7):1006-12. doi: 10.1016/j.ejca.2011.01.016. Epub 2011 Mar 4.

PMID:
21376569
47.

Predicting response to chemotherapy with early-stage lung cancer.

Rosell R, Taron M, Massuti B, Mederos N, Magri I, Santarpia M, Sanchez JM.

Cancer J. 2011 Jan-Feb;17(1):49-56. doi: 10.1097/PPO.0b013e3182091fa3. Review.

PMID:
21263267
48.

Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations.

Rosell R, Molina MA, Costa C, Simonetti S, Gimenez-Capitan A, Bertran-Alamillo J, Mayo C, Moran T, Mendez P, Cardenal F, Isla D, Provencio M, Cobo M, Insa A, Garcia-Campelo R, Reguart N, Majem M, Viteri S, Carcereny E, Porta R, Massuti B, Queralt C, de Aguirre I, Sanchez JM, Sanchez-Ronco M, Mate JL, Ariza A, Benlloch S, Sanchez JJ, Bivona TG, Sawyers CL, Taron M.

Clin Cancer Res. 2011 Mar 1;17(5):1160-8. doi: 10.1158/1078-0432.CCR-10-2158. Epub 2011 Jan 13.

49.

Epigenetic alterations of tumor marker microRNAs: towards new cancer therapies.

Wei J, Xie L, Taron M, Rosell R, Liu B.

Drug News Perspect. 2010 Dec;23(10):655-61. doi: 10.1358/dnp.2010.23.10.1560143. Review.

PMID:
21180651
50.

Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer.

Simonetti S, Molina MA, Queralt C, de Aguirre I, Mayo C, Bertran-Alamillo J, Sanchez JJ, Gonzalez-Larriba JL, Jimenez U, Isla D, Moran T, Viteri S, Camps C, Garcia-Campelo R, Massuti B, Benlloch S, Ramon y Cajal S, Taron M, Rosell R.

J Transl Med. 2010 Dec 18;8:135. doi: 10.1186/1479-5876-8-135.

Supplemental Content

Support Center